Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
06. Juni 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in ChinaUnder strategic collaboration agreement...
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
15. Oktober 2023 19:18 ET
|
Burning Rock Biotech Limited
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test
10. Juli 2023 09:00 ET
|
Shineco, Inc.
Registration with the NMPA, China’s Regulatory Equivalent to the FDA, is a Prerequisite to Marketing and Distribution BEIJING, July 10, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the...
Shineco Subsidiary’s ‘Cardiac 5-Minute Test’ Passes Quality Inspection by China Regulator NMPA
04. April 2023 09:00 ET
|
Shineco, Inc.
Approval Provides Strong Support for the Product’s Marketing in China BEIJING, April 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20. Juli 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
07. Juli 2019 20:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
30. Mai 2019 19:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...